Pancreatitis - Microbiome as Predictor of Severity II

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-01

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to evaluate the orointestinal microbiome and microbial derived metabolome in patients suffering from acute pancreatitis as a biomarker for severity. The main questions it aims to answer are:

* Can the orointestinal microbiome robustly predict the course of acute pancreatitis?
* How does the microbiome impact the severity of an acute pancreatitis?

Buccal/ rectal swabs, plasma and stool is collected from patients with acute pancreatitis within 48h after hospital admission.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics

NCT06230432

Acute Pancreatitis

NOT_YET_RECRUITING

The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study)

NCT05980221

Pancreatic Exocrine Insufficiency

UNKNOWN NA

The Role of Microbiota in Pancreatic Cancer and Precursor Lesions

NCT07250100

Pancreatic Cancer Microbiome

RECRUITING

PROOF: Pancreatitis-associated Risk Of Organ Failure

NCT03075605

Pancreatitis Organ Failure, Multiple

COMPLETED

Oral Microbiome and Pancreatic Cancer

NCT03302637

Pancreatic Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite intensive research, early prediction of the course of acute pancreatitis (AP) is still not satisfactorily possible. Results of a European multicenter study showed that the intestinal microbiome is superior to established scores as a marker of severity in patients with AP. Hereby, a classifier was established using 16 differentially abundant rectal species and systemic inflammatory response syndrome (SIRS) and achieved an AUROC of 85%. Surprisingly, all species in the severe AP group were members of taxonomic families known for their short-chain fatty acid (SFCA) production. This observation contrasts with translational pancreatitis studies in mice. Based on these publications, a clinical trial is currently being initiated to treat severe AP with SCFA (NCT06147635). However, previous well-designed RCT that analyzed the effects of probiotics in predicted severe AP resulted in a worse outcome for patients in the probiotic arm. Consequently, national and international guidelines recommend against the usage of probiotics in AP.

Collectively, more research is needed to further elucidate the role of the oro-intestinal microbiota in the development of severe AP. To validate the results of previously mentioned multicenter study and to profoundly analyze the role of microbial metabolites and the fungeome, patients with AP will be prospectively recruited.

1. Buccal and rectal swabs, stool and plasma will be obtained to analyze the orointestinal microbiome and microbial derived metabolites.
2. Centers from different continents with different ethical background and dietary habits will enroll patients to gain a more generalizable microbial profile.
3. Microbial shifts were observed between severe AP (RAC 3) and mild/ moderate severe (RAC 1+2).
4. It is expected that the microbial compositions change during the inflammatory process upon early phase of pancreatitis. To minimize this microbial alternating effect a short time frame from hospital admission to recruitment (48h) is set.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pancreatitis Acute Pancreatitis With Infected Necrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Revised Atlanta classifiaction (RAC) I - mild

No local or systemic complication

No interventions assigned to this group

Revised Atlanta classifiaction (RAC) II - moderate severe

Local complications as necrosis or fluid collection or organ failure \< 48h

No interventions assigned to this group

Revised Atlanta classifiaction (RAC) III - severe

Organ failure \> 48h

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with initial diagnosis (\< 48h) of acute pancreatitis
* Age ≥ 18 years
* Patients able to understand/ give their written consent

Exclusion Criteria

* Recurrent acute pancreatitis (\>2 previous episodes)
* Clinical or imaging signs of chronic pancreatitis
* Referred patients with length of hospital stay \> 48h

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No